Revenue cycle · Hospital revenue integrity and pharmacy analytics
Craneware
The Craneware Group is a healthcare software company based in Edinburgh, Scotland, whose Trisus platform helps US hospitals manage their chargemaster, revenue integrity, pharmacy spend, and 340B drug programs.
Strong fit
- US hospitals and health systems that want chargemaster and pricing work handled in one tool
- Hospital pharmacy teams managing 340B programs and drug spend
- Revenue integrity teams that want long-standing reference data and hands-on training
Weak fit
- Physician practices and outpatient groups without a hospital chargemaster
- Hospitals looking for a full outsourced billing service
- Buyers who want every add-on included in the base subscription
Bottom line
Craneware sells hospital software for chargemaster management, revenue integrity, and pharmacy and 340B analytics, and about 40% of US hospitals use it. Its Trisus Chargemaster product has been rated Best in KLAS 15 times, and KLAS respondents describe the team as proactive and the training as hands-on. Growth has stalled, with flat revenue in fiscal 2026 and a lower forecast for fiscal 2027, and some customers say support has slipped and that extras cost more.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Craneware's customers are US hospitals and health systems. Revenue integrity, chargemaster, and finance teams use its Trisus software to keep hospital prices and charge codes accurate, find missed charges, and model pricing. Pharmacy teams use it to manage drug spend and 340B programs. About 40% of US hospitals are customers, according to the company's fiscal 2026 results.
Craneware sells its software by subscription, and pricing is by quote. It reported annual recurring revenue of $185 million and customer retention of more than 90% at the end of fiscal 2026. Among companies we review, Turquoise Health works on hospital price transparency and contracts, MDaudit sells billing compliance and revenue integrity audits, and SmarterDx and CodaMetrix use AI to review claims and coding.
Keith Neilson and Gordon Craig founded Craneware in Edinburgh in 1999, and the company listed on London's AIM market in 2007, according to its company history. It bought Sentry Data Systems, a pharmacy and 340B analytics company, in 2021 for about $400 million, Neilson told Daily Business.
In the year to June 30, 2026, revenue was $206.0 million, against $205.7 million the year before, and adjusted EBITDA was $67.1 million. The company reset its fiscal 2027 revenue expectation to about $185 million. Its Trisus Assist AI tool is in use at more than 400 customers, and Trisus Chargemaster was rated Best in KLAS for a 15th time. Craneware also launched Trisus OneLink for medication spend and joined Microsoft as a Frontier partner.
On KLAS, customers credit Craneware with being proactive, available for training, and strong on reference data. The criticisms are that support is weaker than it was and that added features cost extra.
What customers say
What people like
"The Craneware Group has been good. They're very proactive, and they don't charge us for upgrades." KLAS
"For training, The Craneware Group has been very available and hands-on." KLAS
"I use Trisus Chargemaster a lot for setting up new supplies, and the reference piece is amazing." KLAS
What people don't like
"Support is not as good as it used to be, but I still think it's good." KLAS
"Everything costs money, and I don't get paid more." KLAS
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Turquoise Health | 7.8 | 7.4 |
| Craneware | 7.6 | 7.2 |
| SmarterDx | 7.6 | 7.2 |
| CodaMetrix | 7.6 | 7.3 |
| MDaudit | 7.4 | 7.1 |
Pricing
| Item | Detail |
|---|---|
| Model | Software subscriptions for the Trisus platform. Pricing is by quote. |
| What usually drives cost | The number of hospitals covered, which Trisus modules a system licenses, and pharmacy and 340B add-ons. |
| What to ask before you buy | Ask Craneware which upgrades are included in the subscription, which modules cost extra, and what support level comes with the contract. |
Leadership
Recent news
- September 2026: Craneware reported fiscal 2026 revenue of $206.0 million, flat on the prior year, and reset its fiscal 2027 revenue expectation to about $185 million. London Stock Exchange
- July 2026: Craneware found that an unauthorized party had accessed its systems and taken a subset of data. The company said its services were not disrupted. London Stock Exchange
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.